 |
| Ocriplasmin |
The investigational
eye treatment ocriplasmin significantly resolved vitreomacular traction (VMT) and closed
macular holes compared to placebo in patients with vitreomacular
adhesion (VMA). That's the conclusion of two Phase III studies, involving 652 patients, that was published in the New England Journal of Medicine (NEJM), according to a press release from treatment's developer Novartis. VMA, including VMT and macular holes, is an age-related progressive eye disease that may lead to visual distortion, loss in
visual acuity, and central blindness. More than 300,000 patients suffer
from this disease in Europe alone.Read more.
